Trial intelligence / Profile preview

Phase I/II study of [177Lu]Lu-NeoB plus capecitabine in GRPR-positive, ER-positive, HER2-negative metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitor

CTR20241939Phase 2Completed

Sponsor

Novartis

Start

Aug 2025

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules

Countries

1